Emergent Biosolutions Return on Tangible Equity 2010-2022 | EBS

Current and historical return on tangible equity values for Emergent Biosolutions (EBS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Emergent Biosolutions Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $0.16B $0.76B 22.18%
2021-12-31 $0.23B $0.79B 34.48%
2021-09-30 $0.23B $0.64B 37.72%
2021-06-30 $0.30B $0.64B 57.80%
2021-03-31 $0.39B $0.61B 92.88%
2020-12-31 $0.31B $0.52B 104.90%
2020-09-30 $0.17B $0.31B 88.48%
2020-06-30 $0.17B $0.24B 139.63%
2020-03-31 $0.07B $0.10B 118.58%
2019-12-31 $0.05B $0.11B 242.70%
2019-09-30 $0.00B $0.04B -53.33%
2019-06-30 $-0.02B $-0.02B -9.72%
2019-03-31 $0.04B $-0.04B 10.91%
2018-12-31 $0.06B $-0.01B 10.99%
2018-09-30 $0.10B $0.81B 13.13%
2018-06-30 $0.11B $0.78B 15.97%
2018-03-31 $0.07B $0.72B 10.45%
2017-12-31 $0.08B $0.74B 13.70%
2017-09-30 $0.09B $0.59B 15.63%
2017-06-30 $0.07B $0.55B 14.05%
2017-03-31 $0.06B $0.54B 10.89%
2016-12-31 $0.05B $0.52B 9.65%
2016-09-30 $0.05B $0.47B 8.66%
2016-06-30 $0.06B $0.57B 11.49%
2016-03-31 $0.09B $0.56B 16.96%
2015-12-31 $0.06B $0.58B 12.66%
2015-09-30 $0.06B $0.49B 12.95%
2015-06-30 $0.04B $0.45B 10.13%
2015-03-31 $0.04B $0.44B 8.42%
2014-12-31 $0.04B $0.44B 9.34%
2014-09-30 $0.02B $0.41B 5.55%
2014-06-30 $0.01B $0.37B 3.25%
2014-03-31 $0.02B $0.36B 4.31%
2013-12-31 $0.03B $0.45B 6.89%
2013-09-30 $0.03B $0.42B 7.16%
2013-06-30 $0.03B $0.44B 5.77%
2013-03-31 $0.02B $0.43B 5.39%
2012-12-31 $0.02B $0.44B 5.70%
2012-09-30 $0.04B $0.42B 8.93%
2012-06-30 $0.03B $0.42B 7.93%
2012-03-31 $0.04B $0.41B 9.66%
2011-12-31 $0.02B $0.41B 6.32%
2011-09-30 $0.02B $0.38B 5.68%
2011-06-30 $0.03B $0.38B 9.29%
2011-03-31 $0.03B $0.35B 8.86%
2010-12-31 $0.05B $0.37B 17.95%
2010-09-30 $0.03B $0.28B 11.61%
2010-06-30 $0.02B $0.26B 7.26%
2010-03-31 $0.02B $0.25B 9.58%
2009-12-31 $0.03B $0.24B 13.42%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.599B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00